1ALC Stock Chart & Stats
€60.42
-€0.80(-1.31%)
At close: 4:00 PM EDT
€60.42
-€0.80(-1.31%)
Day’s Range― - ―
52-Week Range€34.00 - €105.00
Previous CloseN/A
Volume6.42K
Average Volume (3M)9.85K
Market Cap
€29.07B
Enterprise Value€29.78K
Total Cash (Recent Filing)€1.46B
Total Debt (Recent Filing)€5.31B
Price to Earnings (P/E)52.1
Beta0.42
Next Earnings
Nov 10, 2026EPS Estimate
0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.29
Shares Outstanding499,700,000
10 Day Avg. Volume7,753
30 Day Avg. Volume9,846
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€75.45Price Target Upside24.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)3
Revenue Forecast (FY)€9.51B
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue Growth And Market PositionBroad-based growth across franchises and geographies indicates durable demand rather than reliance on a single product or region. Record contact-lens share and continued growth in newer platforms strengthen Alcon’s competitive position and support recurring revenue over the coming quarters.
Product Innovation And AdoptionStrong adoption of UNITY, PanOptix Pro and TRYPTYR demonstrates effective product innovation and commercial execution. These offerings can expand Alcon’s installed base, procedure-related consumables and premium mix, creating additional durable growth opportunities.
Cash Generation And Conservative LeverageImproving free cash flow combined with conservative leverage gives Alcon financial flexibility to fund launches, support research, manage operating needs and return capital. This balance-sheet capacity reduces dependence on borrowing while preserving options for sustained investment.
Bears Say
Recent Profitability And Return CompressionThe recent decline in net margin and ROE shows that revenue growth has not fully translated into consistent bottom-line returns. If operating costs or pricing pressure persist, weaker profitability could constrain reinvestment efficiency and reduce the benefit of otherwise solid demand.
PowerVision Clinical And Pipeline SetbackEnding the PowerVision programs removes a potential long-term accommodating-IOL growth pathway and reflects a setback in clinical development. It also concentrates future pipeline expectations on other products, increasing the importance of successful execution and adoption elsewhere.
Implantables Competition And Slower GrowthLow implantables growth and heightened competitive launches indicate pressure in a strategically important surgical category. Persistent competition may limit pricing and share gains, making it harder for Alcon to sustain historical growth even as newer products perform well.
Alcon News
1ALC FAQ
What was Alcon Inc’s price range in the past 12 months?
Alcon Inc lowest stock price was €34.00 and its highest was €105.00 in the past 12 months.
What is Alcon Inc’s market cap?
Alcon Inc’s market cap is €29.07B.
When is Alcon Inc’s upcoming earnings report date?
Alcon Inc’s upcoming earnings report date is Nov 10, 2026 which is in 54 days.
How were Alcon Inc’s earnings last quarter?
Alcon Inc released its earnings results on Aug 10, 2026. The company reported €0.721 earnings per share for the quarter, beating the consensus estimate of €0.64 by €0.082.
Is Alcon Inc overvalued?
According to Wall Street analysts Alcon Inc’s price is currently Undervalued.
Does Alcon Inc pay dividends?
Alcon Inc does not currently pay dividends.
What is Alcon Inc’s EPS estimate?
Alcon Inc’s EPS estimate is 0.75.
How many shares outstanding does Alcon Inc have?
Alcon Inc has 499,700,000 shares outstanding.
What happened to Alcon Inc’s price movement after its last earnings report?
Alcon Inc reported an EPS of €0.721 in its last earnings report, beating expectations of €0.64. Following the earnings report the stock price went up 4.284%.
Which hedge fund is a major shareholder of Alcon Inc?
Currently, no hedge funds are holding shares in IT:1ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€75.45 (24.88% Upside)
€75.45 (24.88% Upside)
Blogger Sentiment
Bullish
IT:1ALC Sentiment 89%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.04%
12-Months-Change
Fundamentals
Return on Equity
0.53%
Trailing 12-Months
Asset Growth
-0.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alcon Inc
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
1ALC Company Deck
1ALC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a clearly positive operational and financial quarter: 7% consolidated sales growth, strong equipment performance (UNITY), margin expansion (+250 bps gross margin, +160 bps operating margin), EPS and cash-flow strength, and multiple successful new-product introductions (PanOptix Pro, TRYPTYR, Valeda). Notable negatives included the discontinuation of the PowerVision accommodating IOL program, slower growth in implantables and certain glaucoma products, a few one-time margin items and manufacturability timing for UNITY DX. On balance, the positives — consistent revenue and margin expansion, robust cash generation and multiple high-potential product rollouts and market-share gains — outweigh the setbacks.View all IT:1ALC earnings summaries1ALC Stock 12 Month Forecast
Average Price Target
€75.45
▲(24.88% Upside)
Technical Analysis
Roche Holding AG
―
Straumann Holding AG
―
Siegfried Holding AG
―
Tecan Group AG
―
medmix AG
―